OnDemand WTP Pricing Research

Controlling stent prices may show benefits in short-run, but does long-term damage | The Financial Express

A new study by doctors and policymakers at public hospitals posits that the price cap on coronary stents may have helped a larger number of patients from lower-income groups undergo life-saving angioplasty since their number went up sharply after the price-regulation move. The study, led by Dr Bhanu Duggal, the head of cardiology at AIIMS, Rishikesh, found that the number of patients who underwent procedures involving stents in Maharashtra rose by 43% after the state reduced prices of drug-eluting stents in 2014—while only 40.7% of the patients could afford the high-end stents in 2013, the number jumped to 71.3% in 2015.

All that said, the price-control regime was a bad idea then and is a bad idea now. The effect that the study describes could most likely be temporal, since drug-eluting stents are mostly manufactured by medical-device MNCs, and post 2017, many have either pulled out their state-of-the-art stents from the Indian market or have announced plans to do so.

Read complete article here:

Controlling stent prices may show benefits in short-run, but does long-term damage – The Financial Express.

Post a Comment

WP-SpamFree by Pole Position Marketing